Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. - Wikidata - wikimedia - TriplyDB

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q54426186

about

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors Genetics of myeloproliferative neoplasms Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase The transcription factor Ikaros inhibits cell proliferation by downregulating ANXA4 expression in hepatocellular carcinoma JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.An adult B-cell precursor acute lymphoblastic leukemia with multiple secondary cytogenetic aberrations.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.Regulator of myeloid differentiation and function: The secret life of Ikaros.IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Alternative Splice Variants Modulates Dominant-Negative Function of Helios in T-Cell Leukemia.Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints.Normal and malignant megakaryopoiesis.CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.New JAK2 inhibitors for myeloproliferative neoplasms.Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.B-lineage transcription factors and cooperating gene lesions required for leukemia development.Molecular biology of Philadelphia-negative myeloproliferative neoplasms Genetic and epigenetic alterations of myeloproliferative disorders.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.Inherited predisposition to myeloproliferative neoplasms Genetic basis of MPN: Beyond JAK2-V617F.Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.Ikaros and leukaemia.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.

P2860

Q26777265-37C37E1A-32A9-45A5-82BC-E472A229E2D1 Q26823651-462626B4-A02D-4FDA-AF3B-FC94602CB169 Q33393587-94C7B2EB-F82C-444C-AC79-0E3B4E234BB6 Q33413428-9508ED00-B4DE-4456-BB6A-71F49A874C51 Q33558154-E880403C-6B7C-49CE-AB2D-27D4E4CC9A3F Q33850043-7EFD2287-FC1D-46AD-86E3-71BFEFF4FD98 Q34150008-FCFBE64D-6D3A-4F38-BBD5-7A4261D7926A Q34166859-62D17BA2-4FF4-475E-AA46-82E7C4C60F4E Q34233335-0834DE5A-1C84-4F18-B107-B3939E84E435 Q34302770-56AD6F5E-9A91-4FCD-922D-3A8BD68C2127 Q34348505-1B5F931E-8A54-490B-8FA5-AB26397410B0 Q34629928-032C2380-079F-4591-8A3F-4833DDEFFCB9 Q34786517-CD1F17D2-652E-42E4-98B9-6DCEC2E8F365 Q35103926-408D7378-D9D6-43B6-A810-92518259A40E Q35835653-F46E7934-C1C8-440B-9969-CBA713B1705A Q35995222-AB38AF94-49ED-4BEF-B520-361447990E87 Q36001930-EACCB193-0F7B-4EC0-9C1C-80FD8B28B17F Q36147014-E9E4F860-C8FF-452C-9DEE-870E04DC82B8 Q36594686-454199C9-2C0A-400D-8FE0-718AA8DE0B12 Q36612537-B4EA4207-657E-485D-B36D-3A8FEC685A6E Q36709009-6EEC2148-9D79-414D-AE2E-2720CA38623B Q36730409-85FCBDCE-75BB-43BD-9FC6-36EDBCF2A1AE Q36858928-67889046-FAC6-452E-A5C3-18DEB7E8D526 Q36909019-6611F16D-41CB-4BC5-AD6D-FA45E8BD54C6 Q36964853-D0884419-253F-4A42-9F93-3EEC3D6697C9 Q37833893-E36289BC-D490-4F71-9323-3DE23CE1DDA0 Q37869152-F447D448-7175-475F-AE81-D16660D6B27C Q37877727-AAD5B9C5-0388-423A-A73F-F2B592CE10CE Q37968531-1FE74831-B00C-4DDD-B060-72C9875AB871 Q38014534-813DC999-E784-42E8-8E86-6B142AF7E112 Q38044736-60AD20D5-AA5F-43BA-BEB8-FC55D1AAF25B Q38050656-AFD347ED-2F60-4E0C-B534-64715D968E75 Q38050756-B807F740-60B6-48F2-BE2E-2FEFBAB5C087 Q38066786-2F78F7BC-1579-446A-A532-D097D2C54EF8 Q38100790-9CBA1149-B3A6-4EA9-BCA3-984574F8AA04 Q38127417-5E684782-1E35-4035-A8CF-05A9650A6531 Q38159973-3922F137-0560-4C2F-8045-C4504278A8AD Q38329285-C3D684D1-F858-4BA8-9256-20A7F5FE8EA3 Q38371003-592AA258-85B9-41C0-970F-B0EE85980FC0 Q38683077-0E4F27D8-6071-4CDB-B30C-DA5C2FE7F591

P2860

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q54426186

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

@en

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

@nl

type

label

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

@en

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

@nl

prefLabel

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

@en

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

@nl

P1433

Q54426186-1E171EE6-050A-4881-A8EA-AA419FA72257

P1476

Q54426186-51739CBA-B94F-44C4-9D9B-ECECCA547A25

P2093

Q54426186-34FA4247-A500-405E-B959-506F2E47ABB1

Q54426186-8A0096D7-4BE6-45E7-BA72-1B81B9A0743F

Q54426186-9C552AAA-7E8E-4D0E-9DF6-9978FC9DB987

Q54426186-B31B03E0-BDCB-4D6E-8879-BC760CB39655

Q54426186-B81F1E3C-DAE0-4666-8AE9-96C0229C4E39

Q54426186-C3E39B8E-226D-45E5-8076-F4BE4F1906D4

Q54426186-C581BA58-71A3-4417-9E06-B14C307EEDFB

Q54426186-CF795CE0-7927-4D06-BEC6-0D3329C41E7D

P2860

Q54426186-0199FFAF-DF80-41E3-A2ED-232911CDA56B

Q54426186-01AF3CEF-9079-4CD7-A253-88B3FC477877

Q54426186-0F852710-9295-4D94-8ACB-1E2837CDC767

Q54426186-134FBD5D-70DF-4928-9D36-C8DAAFCAA043

Q54426186-2B8C5609-97BF-426A-8A87-3C1F7E6EE6FA

Q54426186-2BF3F047-74F1-4B23-8764-11EEAB6A327B

Q54426186-36ACAC85-DF4D-4025-B82A-3BAF750E4596

Q54426186-3A527C57-8FA5-4C3A-AB41-ED1FB60D88FE

Q54426186-3D31DE5D-B4DF-49F8-B491-82ACA646BFB8

Q54426186-3DA472E2-5FE7-4D53-9BE3-5BA813CFD7EC

P2888

Q54426186-5A8B3C4E-3EDF-411F-BDE5-C88FF4CD3AC6

P304

Q54426186-D9A7C008-3F41-4459-8D0E-FC0803380A81

P31

Q54426186-98956310-9B34-47FF-B670-3D8D4CB2F575

P356

Q54426186-19C5A341-3AC9-44D1-860E-6E40FB92DCC1

P433

Q54426186-424EC85A-4B85-4CD6-9C70-48F76DEB092E

P478

Q54426186-FDBA21DB-B8B3-4A01-872F-6EDE601199C1

P50

Q54426186-5CB0B936-F1B1-4816-9E25-5ADEB9AF2911

Q54426186-CAC4D5C4-2AAA-48A0-8348-40F7878C8A25

Q54426186-EBE70F03-57C1-4EE7-BA87-3A25C85F6DB5

Q54426186-EC6E9CBD-3861-4F9A-B783-62D2CCB6684B

P577

Q54426186-CDD57CC6-944B-4C0A-881A-F6927646BA67

P5875

Q54426186-85E84998-6486-487C-A4A4-1ED5B2A6DD13

P698

Q54426186-F1CBF2D4-66DE-4D1D-B87B-CA4A54D2A53F

P356

P1433

P1476

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

@en

P2093

B Gisslinger

http://www.w3.org/2001/XMLSchema#string

D Olcaydu

http://www.w3.org/2001/XMLSchema#string

E Rumi

http://www.w3.org/2001/XMLSchema#string

H Gisslinger

http://www.w3.org/2001/XMLSchema#string

M Cazzola

http://www.w3.org/2001/XMLSchema#string

R Jäger

http://www.w3.org/2001/XMLSchema#string

T Berg

http://www.w3.org/2001/XMLSchema#string

T Klampfl

http://www.w3.org/2001/XMLSchema#string

P2860

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Recurring mutations found by sequencing an acute myeloid leukemia genome

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.

Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

Multiple hematopoietic defects and delayed globin switching in Ikaros null mice

The Ikaros gene is required for the development of all lymphoid lineages

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

P2888

P304

1290-1298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2010.99

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Robert Kralovics

Ashot S Harutyunyan

Francesco Passamonti

P577

2010-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44636151

http://www.w3.org/2001/XMLSchema#string

P698

20508609

http://www.w3.org/2001/XMLSchema#string